Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).

Trial Details

NCT ID
NCT04912765
Phase
PHASE2
Sponsor
National Cancer Centre, Singapore
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Neoantigen Dendritic Cell Vaccine
  • Nivolumab
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • HCC specific criteria (Group A):
  • Participants must have either newly diagnosed or recurrent HCC, confirmed by histology/cytology or clinically by AASLD criteria in cirrhotic subjec…
  • Up to three tumours, at least one with a diameter \> 3cm
  • More than three tumours, none with a diameter \> 5 cm

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →